Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 13/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.42 |
| ▸ | STIM1 | Q13586 | 1/20 | 0.38 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | PSD | A5PKW4 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.37 |
| ▸ | PDE1A | P54750 | 1/20 | 0.36 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.36 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22791107 | 0.91 | STIM1 (0.43) | PTGER1MRGPRX4STIM1ORAI1HDAC1 | |
| SCHEMBL21786530 | 0.88 | MAPT (0.40) | MRGPRX4STIM1ORAI1 | |
| SCHEMBL21786411 | 0.88 | KCNT1 (0.36) | PTGER1MRGPRX4STIM1ORAI1 | |
| SCHEMBL21786459 | 0.86 | STIM1 (0.35) | PTGER1MRGPRX4STIM1ORAI1CYP2C9 | |
| SCHEMBL23913085 | 0.85 | MRGPRX4 (0.40) | PTGER1MRGPRX4CYP2C9 | |
| SCHEMBL21786450 | 0.84 | CYP11B1 (0.39) | PTGER1STIM1ORAI1CYP2C9 | |
| SCHEMBL21786416 | 0.83 | SLC6A4 (0.41) | PTGER1MRGPRX4STIM1ORAI1CYP2C9 | |
| SCHEMBL21786589 | 0.83 | STIM1 (0.37) | MRGPRX4STIM1ORAI1CYP2C9 | |
| SCHEMBL21786611 | 0.83 | SLC6A4 (0.39) | PTGER1STIM1ORAI1CYP2C9 | |
| SCHEMBL21786465 | 0.83 | SLC6A4 (0.39) | MRGPRX4STIM1ORAI1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210395206-A1 | SUBSTITUTED HETEROCYCLES AS c-MYC TARGETING AGENTS | NORTHWESTERN UNIVERSITY | 2021-12-23 | — | — | US | disclosed |
| US-11142504-B2 | Substituted heterocycles as c-MYC targeting agents | NORTHWESTERN UNIVERSITY (US) | 2021-10-12 | — | — | US | disclosed |
| WO-2020257261-A1 | SUBSTITUTED HETEROCYCLES AS c-MYC TARGETING AGENTS | NORTHWESTERN UNIVERSITY (US) | 2020-12-24 | — | — | WO | disclosed |
| US-20200392116-A1 | SUBSTITUTED HETEROCYCLES AS c-MYC TARGETING AGENTS | NORTHWESTERN UNIVERSITY (US) | 2020-12-17 | — | — | US | disclosed |
| WO-2020046382-A1 | SUBSTITUTED HETEROCYCLES AS C-MYC TARGETING AGENTS | NORTHWESTERN UNIVERSITY (US) | 2020-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392116-A1 | SUBSTITUTED HETEROCYCLES AS c-MYC TARGETING AGENTS | MYC, MYCBP, MYCBP2 | PTGER1 4862/4885MRGPRX4 3150/4885STIM1 3524/4885 |
| US-20210395206-A1 | SUBSTITUTED HETEROCYCLES AS c-MYC TARGETING AGENTS | MYC, MYCBP, MYCBP2 | PTGER1 4862/4885MRGPRX4 3150/4885STIM1 3524/4885 |
| US-11142504-B2 | Substituted heterocycles as c-MYC targeting agents | MYC, MYCBP, MYCBP2 | PTGER1 4862/4885MRGPRX4 3150/4885STIM1 3524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.